Kairos Pharma (NYSE American: KAPA)ย announced it will participate in the DealFlow Discovery Conference to be held Jan. 28โ29, 2026, at the Borgata Hotel, Casino & Spa in Atlantic City, N.J. The company said Chief Scientific Officer Neil Bhowmick will deliver a company presentation and conduct one-on-one meetings with investors during the event as Kairos continues advancing its clinical-stage oncology programs.
To view the full press release, visit https://ibn.fm/0CBmk
About Kairos Pharma Ltd.
Based in Los Angeles, California, Kairos Pharma Ltd. (ย NYSE American: KAPAย ) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV-105, is an antibody that targets CD105โa protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.ย
NOTE TO INVESTORS:ย The latest news and updates relating to KAPA are available in the companyโs newsroom atย https://ibn.fm/KAPA
About TinyGems
TinyGemsย is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text โGemsโ to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visitย https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published:ย https://www.TinyGems.com/Disclaimer
TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com
TinyGems is powered byย IBN
